Recent News

• 06.11.2026 - Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
• 05.11.2026 - Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.04.2026 - Kyntra Bio to Report First Quarter 2026 Financial Results
• 04.08.2026 - Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
• 03.16.2026 - Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 03.09.2026 - Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
• 02.23.2026 - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
• 02.17.2026 - Kyntra Bio to Participate in Upcoming Investor Conferences
• 12.02.2025 - FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
• 11.10.2025 - FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 06.09.2026 - 8-K Current report
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - 4/A Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.11.2026 - 8-K Current report
• 05.11.2026 - EX-99.1 EX-99.1
• 04.27.2026 - ARS Annual Report to Security Holders